Rita Jain's Net Worth
$4.8 Million
Who is Rita Jain?
Rita Jain has an estimated net worth of $4.8 Million. This is based on reported shares across multiple companies, which include ANAPTYSBIO, INC, ChemoCentryx, Inc., Immunovant, Inc., Akebia Therapeutics, Inc., Provention Bio, Inc., and Celldex Therapeutics, Inc..
SEC CIK
Rita Jain's CIK is 0001707797
Past Insider Trading and Trends
2021 was Rita Jain's most active year for acquiring shares with 12 total transactions. Rita Jain's most active month to acquire stocks was the month of February. 2022 was Rita Jain's most active year for disposing of shares, totalling 10 transactions. Rita Jain's most active month to dispose stocks was the month of September. 2021 saw Rita Jain paying a total of $0.00 for 1,210,471 shares, this is the most they've acquired in one year. In 2018 Rita Jain cashed out on 8,659 shares for a total of $77,411.46, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
ANAPTYSBIO, INC (ANAB) Snapshot price: $35.9
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 4.53K |
—
|
—
| 4.53K |
Jun 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ChemoCentryx, Inc. No price found
EVP, Chief Medical Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -35.86K |
—
|
—
|
0
|
Oct 20
| |||
Form 4
| +27.46% | 7.73K |
—
|
—
| 35.86K |
May 20
| |||
Form 4
| +22.94% | 5.25K |
—
|
—
| 28.14K |
Mar 27
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 5
| |||
Form 4
| +25.57% | 4.66K |
—
|
—
| 22.89K |
May 20 - May 21
| |||
Form 4
| +40.47% | 5.25K |
—
|
—
| 18.23K |
Mar 27
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 21
| |||
Form 4
| +67.98% | 5.25K |
—
|
—
| 12.97K |
Mar 27
| |||
Form 4
|
∞
| 7.72K |
—
|
—
| 7.72K |
May 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 27
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Immunovant, Inc. (IMVT) Snapshot price: $34
Chief Medical Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4/A
| +546.83% | 109.36K |
—
|
—
| 129.37K |
Mar 19
| |||
Form 4
| +546.83% | 109.36K |
—
|
—
| 129.37K |
Mar 19
| |||
Form 4
|
∞
| 20K |
—
|
—
| 20K |
Jan 22
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Akebia Therapeutics, Inc. (AKBA) Snapshot price: $1.36
SVP, Chief Medical Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -4.38% | -4.41K |
$7.70 | -$33,949.30 | 96.33K |
Apr 11
| |||
Form 4
| +385.71% | 80K |
—
|
—
| 100.74K |
Feb 28
| |||
Form 4
| -29.45% | -8.66K |
$8.94 | -$77,411.46 | 20.74K |
Dec 12
| |||
Form 4
|
∞
| 29.4K |
—
|
—
| 29.4K |
Feb 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 31
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Provention Bio, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 27
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||